The Role of Aflibercept (Eylea) Intravitreal Injection in Treatment of Resistant or CNV Complicated CSR (Central Serous Retinopathy)

Purpose to evaluate the benefit and side effects of intravitreal Aflibercept (Eylea) injection in the treatment of cases that are resistant to previous treatment choices or complicated with CNV due to central serous retinopathy [CSR] Methods It is retrospective study on 72 patients with diagnosed to have CSR and follow up for 12-18 months we can consider that there is complete resolution if subretinal fluid disappeare for 3 months from last intravitreal injection of Eylea We planned this research to demonstrate the efficiency of aflibercept intravitreal injection in the treatment of cases that resistant to treatment or complicated with CNV secondary to CSR.